glp 1 agonist nash Resmetirom and GLP-1 agonists for MASH: complementary rather than exclusive Therapeutic Approach to NAFLD-NASH |
Description
As important as the first two are, the third can't be underestimated
Liu L, et al
In a model of lipopolysaccharide (LPS)-induced visceral hypersensitivity and repeated water avoidance stress (WAS) in rats, liraglutide effectively reduced visceral allodynia by suppressing pro-inflammatory cytokine production and improving colonic barrier integrity [59]
doi: 10.2337/dc16-2725
Exenatide alters myocardial glucose transport and uptake depending on insulin resistance and increases myocardial blood flow in patients with type 2 diabetes
The LEAN trial with liraglutide and a phase 2 trial of semaglutide in patients with non-alcoholic steatohepatitis (NASH) showed improvements in liver histology and reductions in hepatic inflammation markers
